FIELD: pharmaceutics.
SUBSTANCE: invention refers to pharmaceutical industry, namely to a method of treating amyotrophic lateral sclerosis. Method of treating amyotrophic lateral sclerosis in a subject, comprising administering to said subject of 4-((2-(((1R,2R)-2-hydroxycyclohexyl)amino)benzo[d]thiazol-6-yl)oxy)-N-methylpicolinamide or a pharmaceutically acceptable salt thereof for period of 4 days, followed by a period of no administration of 10 days, and in a daily dose of 600 mg/day, 800 mg/day or 1200 mg/day.
EFFECT: use of the invention provides reduced probability of undesirable phenomena, namely reduced probability of AST and ALT level increase.
10 cl, 13 dwg, 10 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO CSF-1R | 2020 |
|
RU2751249C1 |
| A NEW COMBINATION FOR USE IN THE TREATMENT OF MALIGNANT NEOPLASMS | 2016 |
|
RU2742494C2 |
| MOLECULES OF ANTIBODIES TO CD73 AND THEIR APPLICATION WAYS | 2018 |
|
RU2791192C2 |
| MOLECULES OF ANTIBODIES TO PD-1 AND THEIR USE | 2016 |
|
RU2788092C2 |
| 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USE THEREOF IN TREATING DISEASES ASSOCIATED WITH ZINC FINGER PROTEIN 2 OF IKAROS (IKZF2) FAMILY | 2019 |
|
RU2815714C2 |
| ANTIBODIES TO ENTPD2, TYPES OF COMBINATION THERAPY AND METHODS FOR USING ANTIBODIES AND TYPES OF COMBINATION THERAPY | 2019 |
|
RU2790991C2 |
| METHOD FOR PREVENTION AND TREATMENT OF CANCER METASTASES AND BONE LOSS CAUSED BY CANCER METASTASES | 2007 |
|
RU2470665C2 |
| COMPOSITION FOR TREATING IGF-1R EXPRESSING CANCER | 2016 |
|
RU2728568C2 |
| ANTIBODIES TO CD40 AND THEIR APPLICATION METHODS | 2017 |
|
RU2752049C2 |
| CONJUGATES OF BINDER AND ACTIVE SUBSTANCE (ADC) HAVING ENZYMATICALLY CLEAVABLE GROUPS | 2017 |
|
RU2761390C2 |
